Molecular analysis of 11β-hydroxysteroid dehydrogenase and its role in the syndrome of apparent mineralocorticoid excess

Steroids

Volumn 62, Issue 1, 1997, Pages 83-88

  White, Perrin C ^a   Mune, Tomoatsu ^a   Rogerson, Fraser M ^a   Kayes, Kathleen M ^a   Agarwal, Anil K ^a  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

aldosterone; cortisol; cortisone; hypertension; kidney; mineralocorticoid receptor

Indexed keywords

11BETA HYDROXYSTEROID DEHYDROGENASE; ALDOSTERONE; CORTISONE; ISOENZYME;

CONFERENCE PAPER; ENZYME CHEMISTRY; GENE MUTATION; HUMAN; HYPERTENSION; HYPOKALEMIA; PLASMA RENIN ACTIVITY; SYNDROME;

11-BETA-HYDROXYSTEROID DEHYDROGENASES; ALLELES; ANIMALS; CLONING, MOLECULAR; DNA, COMPLEMENTARY; FEMALE; HUMANS; HYDROXYSTEROID DEHYDROGENASES; HYPERTENSION; MINERALOCORTICOIDS; MUTATION; PLACENTA; PREGNANCY; RATS; SYNDROME; TRANSCRIPTION, GENETIC;

EID: 0031022385     PISSN: 0039128X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0039-128X(96)00164-X     Document Type: Conference Paper

References (43)

1. Ulick S, Levine LS, Gunczler P, Zanconato G, Ramirez LC, Rauh W, Rosler A, Bradlow HL, New MI (1979). A syndrome of apparent mineralocorticoid excess associated with defects in the peripheral metabolism of cortisol. J Clin Endocrinol Metab 49:757-764.
2. Oberfield SE, Levine LS, Carey RM, Greig F, Ulick S, New MI (1983). Metabolic and blood pressure responses to hydrocortisone in the syndrome of apparent mineralocorticoid excess. J Clin Endocrinol Metab 56:332-339.
3. Shackleton CH, Rodriguez J, Arteaga E, Lopez JM, Winter JS (1985). Congenital 11 beta-hydroxysteroid dehydrogenase deficiency associated with juvenile hypertension: corticosteroid metabolite profiles of four patients and their families. Clin Endocrinol (Oxf) 22:701-712.
4. Monder C, Shackleton CH, Bradlow HL, New MI, Stoner E, Iohan F, Lakshmi V (1986). The syndrome of apparent mineralocorticoid excess: its association with 11 beta-dehydrogenase and 5 beta-reductase deficiency and some consequences for corticosteroid metabolism. J Clin Endocrinol Metab 63:550-557.
5. Stewart PM, Wallace AM, Valentino R, Burt D, Shackleton CH, Edwards CR (1987). Mineralocorticoid activity of liquorice: 11-beta-hydroxysteroid dehydrogenase deficiency comes of age. Lancet 2:821-824.
6. Monder C, Stewart PM, Lakshmi V, Valentino R, Burt D, Edwards CR (1989). Licorice inhibits corticosteroid 11 beta-dehydrogenase of rat kidney and liver: in vivo and in vitro studies. Endocrinology 125:1046-1053.
7. Arriza JL, Weinberger C, Cerelli G, Glaser TM, Handelin BL, Housman DE, Evans RM (1987). Cloning of human mineralocorticoid receptor complementary DNA: structural and functional kinship with the glucocorticoid receptor. Science 237:268-275.
8. Krozowski ZS, Funder JW (1983). Renal mineralocorticoid receptors and hippocampal corticosterone binding species have identical intrinsic steroid specificity. Proc Natl Acad Sci USA 80:6056-6060.
9. Edwards CR, Stewart PM, Burt D, Brett L, McIntyre MA, Sutanto WS, de Kloet ER, Monder C (1988). Localisation of 11 beta-hydroxysteroid dehydrogenase - tissue specific protector of the mineralocorticoid receptor. Lancet 2:986-989.
10. Funder JW, Pearce PT, Smith R, Smith AI (1988). Mineralocorticoid action: target tissue specificity is enzyme, but not receptor, mediated. Science 242:583-585.
11. Lakshmi V, Monder C (1988). Purification and characterization of the corticosteroid 11 beta-dehydrogenase component of the rat liver 11 beta-hydroxysteroid dehydrogenase complex. Endocrinology 123:2390-2398.
12. Agarwal AK, Monder J, Eckstein B, White PC (1989). Cloning and expression of rat cDNA encoding corticosteroid 11 beta-dehydrogenase. J Biol Chem 264:18939-18943.
13. Agarwal AK, Tusie-Luna MT, Monder C, White PC (1990). Expression of 11 beta-hydroxysteroid dehydrogenase using recombinant vaccinia virus. Mol Endocrinol 4:1827-1832.
14. Tannin GM, Agarwal AK, Monder C, New MI, White PC (1991). The human gene for 11 beta-hydroxysteroid dehydrogenase. Structure, tissue distribution, and chromosomal localization. J Biol Chem 266:16653-16658.
15. Nikkila H, Tannin GM, New MI, Taylor NF, Kalaitzoglou G, Monder C, White PC (1993). Defects in the HSD11 gene encoding 11β-hydroxysteroid dehydrogenase are not found in patients with apparent mineralocorticoid excess or 11-oxoreductase deficiency. J Clin Endocrinol Metab 77:687-691.
16. Yang K, Smith CL, Dales D, Hammond GL, Challis JR (1992). Cloning of an ovine 11 beta-hydroxysteroid dehydrogenase complementary deoxyribonucleic acid: tissue and temporal distribution of its messenger ribonucleic acid during fetal and neonatal development. Endocrinology 131:2120-2126.
17. Rundle SE, Funder JW, Lakshmi V, Monder C (1989). The intrarenal localization of mineralocorticoid receptors and 11 beta-dehydrogenase: immunocytochemical studies. Endocrinology 125: 1700-1704.
18. Rusvai E, Naray-Fejes-Toth A (1993). A new isoform of 11 beta-hydroxysteroid dehydrogenase in aldosterone target cells. J Biol Chem 268:10717-10720.
19. Brown RW, Chapman KE, Edwards CR, Seckl JR (1993). Human placental 11 beta-hydroxysteroid dehydrogenase: evidence for and partial purification of a distinct NAD-dependent isoform. Endocrinology 132:2614-2621.
20. Brown RW, Chapman KE, Murad P, Edwards CR, Seckl JR (1996). Purification of 11ß-hydroxysteroid dehydrogenase type 2 from human placenta utilizing a novel affinity labelling technique. Biochem J 313:997-1005.
21. +-dependent isoform of 11 beta-hydroxysteroid dehydrogenase: cloning and characterization of cDNA from sheep kidney. J Biol Chem 269:25959-25962.
22. Albiston AL, Obeyesekere VR, Smith RE, Krozowski ZS (1994). Cloning and tissue distribution of the human 11-HSD type 2 enzyme. Mol Cell Endocrinol 105:R11-R17.
23. Wu L, Einstein M, Geissler WM, Chan HC, Elliston KO, Andersson S (1993). Expression cloning and characterization of human 17 beta-hydroxysteroid dehydrogenase type 2, a microsomal enzyme possessing 20 alpha-hydroxysteroid dehydrogenase activity. J Biol Chem 268:12964-12969.
24. Persson B, Krook M, Jornvall H (1991). Characteristics of short-chain alcohol dehydrogenases and related enzymes. Eur J Biochem 200:537-543.
25. Obeid J, White PC (1992). Tyr-179 and Lys-183 are essential for enzymatic activity of 11 beta-hydroxysteroid dehydrogenase. Biochem Biophys Res Commun 188:222-227.
26. Ghosh D, Weeks CM, Grochulski P, Duax WL, Erman M, Rimsay RL, Orr JC (1991). Three-dimensional structure of holo 3 alpha,20 beta-hydroxysteroid dehydrogenase: a member of a short-chain dehydrogenase family. Proc Natl Acad Sci USA 88:10064-10068.
27. Agarwal AK, Rogerson FM, Mune T, White PC (1995). Gene structure and chromosomal localization of the human HSD11K gene encoding the kidney (type 2) isozyme of 11ß-hydroxysteroid dehydrogenase. Genomics 29:195-199.
28. Mune T, Rogerson FM, Nikkila H, Agarwal AK, White PC (1995). Human hypertension caused by mutations in the kidney isozyme of 11 beta-hydroxysteroid dehydrogenase. Nature Genet 10:394-399.
29. Wilson RC, Krozowski ZS, Li K, Obeyesekere VR, Razzaghy-Azar M, Harbison MD, Wei JQ, Shackleton CH, Funder JW, New MI (1995). A mutation in the HSD11B2 gene in a family with apparent mineralocorticoid excess. J Clin Endocrinol Metab 80:2263-2266.
30. Wilson RC, Harbison MD, Krozowski ZS, Funder JW, Shackleton CH, Hanauske-Abel HM, Wei JQ, Hertecant J, Moran A, Neiberger RE, Balfe JW, Fattah A, Daneman D, Licholai T, New MI (1995). Several homozygous mutations in the gene for 11β-hydroxysteroid dehydrogenase type 2 in patients with apparent mineralocorticoid excess. J Clin Endocrinol Metab 80:3145-3150.
31. Stewart PM, Krozowski ZS, Gupta A, Milford DV, Howie AJ, Sheppard MC, Whorwood CB (1996). Hypertension in the syndrome of apparent mineralocorticoid excess due to mutation of the 11β-hydroxysteroid dehydrogenase type 2 gene. Lancet 347:88-91.
32. Mune T, White PC (1996). Apparent mineralocorticoid excess: genotype is correlated with biochemical phenotype. Hypertension 27: 1193-1199.
33. m 11β-hydroxysteroid dehydrogenase type II enzyme in a family with apparent mineralocorticoid excess. J Clin Endocrinol Metab 80:3381-3383.
34. Tusie-Luna MT, Traktman P, White PC (1990). Determination of functional effects of mutations in the steroid 21-hydroxylase gene (CYP21) using recombinant vaccinia virus. J Biol Chem 265: 20916-20922.
35. Gruol DJ, Bourgeois S (1994). Expression of the mdr1 P-glycoprotein gene: a mechanism of escape for glucocorticoid-induced apoptosis. Biochem Cell Biol 72:561-571.
36. Edwards CR, Benediktsson R, Lindsay RS, Seckl JR (1993). Dysfunction of placental glucocorticoid barrier: link between fetal environment and adult hypertension? Lancet 341:355-357.
37. Benediktsson R, Lindsay RS, Noble J, Seckl JR, Edwards CR (1993). Glucocorticoid exposure in utero: new model for adult hypertension. Lancet 341:339-341.
38. Barker DJ, Bull AR, Osmond C, Simmonds SJ (1990). Fetal and placental size and risk of hypertension in adult life. Br Med J 301: 259-262.
39. Stewart PM, Rogerson FM, Mason JI (1995). Type 2 11 beta-hydroxysteroid dehydrogenase messenger ribonucleic acid and activity in human placenta and fetal membranes: its relationship to birth weight and putative role in fetal adrenal steroidogenesis. J Clin Endocrinol Metab 80:885-890.
40. Lifton RP (1995). Genetic determinants of human hypertension. Proc Natl Acad Sci USA 92:8545-8551.
41. Smithies O, Kim HS (1994). Targeted gene duplication and disruption for analyzing quantitative genetic traits in mice. Proc Natl Acad Sci USA 91:3612-3615.
42. + dependent 11β-hydroxysteroid dehydrogenase (HSD11K) gene in JEG-3 human choriocarcinoma cells. Mol Cell Endocrinol (in press).
43. Briggs MR, Kadonaga JT, Bell SP, Tjian R (1986). Purification and biochemical characterization of the promoter-specific transcription factor, Sp1. Science 234:47-52.